New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 30, 2014
06:33 EDTAVEOAveo and Astellas discontinue Phase 2 trial of tivozanib in breast cancer
Aveo and Astellas Pharma have jointly decided to discontinue the BATON - Biomarker Assessment of Tivozanib in ONcology - breast cancer clinical trial, a Phase 2 study in patients with locally recurrent or metastatic triple negative breast cancer, due to insufficient enrollment. All committed expenses related to the BATON-BC study are shared equally between AVEO and Astellas.
News For AVEO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 11, 2014
09:17 EDTAVEOOn The Fly: Pre-market Movers
UP AFTER EARNINGS: FMSA Holdings (FMSA), up 4.7% following third quarter results. ALSO HIGHER: AVEO Pharmaceuticals (AVEO), up 7.6% after entering agreement with Ophthotech (OPHT) to license tivozanib... Ophthotech is 2.1% higher in pre-market trading... Galena Biopharma (GALE), up 3.6% after first patient dosed in NeuVax and Herceptin combination Phase 2 trial... Yamana Gold (AUY), up 3% after being upgraded to Overweight from Neutral at HSBC... Ambac Financial (AMBC), up 3.1% after being upgraded to Neutral from Sell at MKM Partners... China Finance (JRJC), up 12.4% after announcing a new partnership with Great Wall Securities... Zynga (ZNGA), up 5.7% after being upgraded on mobile business growth at Jefferies... Fiat Chrysler (FCAU), up 2.2% after being initiated with a Conviction Buy at Goldman. DOWN AFTER EARNINGS: Applied Optoelectronics (AAOI), down 10.7%... Ekso Bionics (EKSO), down 2.2%. ALSO LOWER: Alibaba Group (BABA), down 1.6% following comments made by vice chairman Joseph Tsai in an interview.
06:44 EDTAVEOAveo Pharmaceuticals enters into agreement with Ophthotech for VEGF
Subscribe for More Information
06:37 EDTAVEOOphthotech enters into with Aveo Pharmaceuticals to license tivozanib
Ophthotech (OPHT) has entered into an exclusive research and option agreement with Aveo Pharmaceuticals (AVEO) to license tivozanib, a small molecule vascular endothelial growth factor, or VEGF, tyrosine kinase inhibitor, for the treatment of non-oncologic conditions of the eye. Under the terms of the agreement, Ophthotech will pay an upfront fee of $500,000 for exclusive rights to investigate this compound’s potency and potential as an ocular formulation. Ophthotech is solely responsible for the ocular formulation and development of this compound, which will focus initially on a sustained release formulation as a treatment for the maintenance phase of wet AMD therapy. Under the agreement, upon completion of Ophthotech’s initial analysis, if Ophthotech elects to continue the development of an ocular formulation of this anti-VEGF therapy, Ophthotech will pay additional fees based upon Ophthotech’s submission of an Initial New Drug application and upon the demonstration of proof of concept in humans. If Ophthotech exercises its option for an exclusive worldwide license for the compound for ocular indications, Ophthotech will pay a license fee, and development, regulatory and sales-based milestones, if achieved, as well royalties on commercial sales.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use